Reduction of visible bone metastases by clodronate therapy in breast cancer

The current report describes a 57-year-old patient with multiple bone metastases 14 years after her initial treatment for breast cancer. The only therapy the patient received for her osteolytic lesions was oral clodronate (800 mg/daily), as she refused any other kind of treatment. On bone scintigraphy the number of visible bone metastases diminished slowly and after two years only a few minor lesions could be seen. Together with this report the value of oral clodronate as anti-osteolytic therapy in breast cancer patients is discussed.

Bone metastases; Breast cancer; Clodronate therapy; Reduction

[1] Theriault R. L.: "Medical treatment of bone metastases". In: "Diseases of the Breast". J. R. Harris, M. E. Lippman, M. Morrow, C. K. Osborne, Philadelphia, Lippincott Williams & Wilkins, 1999, 921.

[2] Mundy G. R., Guise T. A., Yoneda T.: "Biology of bone metastases". In: "Diseases of the Breast". J. R. Harris, M. E. Lippman, M. Morrow, C.K. Osborne, Philadelphia, Lippincott Williams & Wilkns,1999, 911.

[3] Coleman R. E., Rubens R. D.: "The clinical course of bone metastases from breast cancer". Br. J. Cancer , 1987, 55, 61.

[4] Coleman R. E.: "Biphosphonates in the prevention and treatment of metastatic bone disease". Breast, 1999, 8, 57.

[5] Hortobagyi G. N., Theriault R. L., Lipton A., Porter L., Blayney D., Sinoff C. et al.: "Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group". J. Clin. Oncol., 1998, 16, 2038.

[6] Kanis J. A., Powles T., Paterson A. H., McCloskey E. V., Ashley S.: "Clodronate decreases the frequency of skeletal metastases in women with breast cancer". Bone, 1996, 19, 663.

[7] Powles T. J., McCloskey E., Paterson A.H., Ashley S., Tidy V. A., Nevantaus A. et al.: "Oral clodronate and reduction in loss of bone mineral denisty in women with operable primary breast cancer" J. Natl. Cancer Inst., 1998, 90, 704.

[8] Balch C. M., Singletary S. E., Bland K. I.: "Clinical decisionmaking in early breast cancer". Ann. Surg., 1993, 217, 207.

[9] Fleish H. A.: "Biphosphonates: preclinical aspects and use in osteoporosis". Ann. Med., 1997, 29, 55.

[10] Diel I. J., Solomayer E.-F., Costa S. D., Golian C., Goerner R., Wall wiener D. et al.: "Reduction in new metastases in breast cancer with adjuvant clodronate treatment". N. Engl. J. Med., 1998, 339,357.